Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 6 art units • 8 examiners • 0 of 9 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Elanco Animal Health GmbH has 8 pending office actions in Biotechnology & Pharmaceuticals. The docket includes 7 distinct examiners across 5 distinct art units, showing that the applications are spread across multiple examination channels while several matters share examiner or art-unit coverage.
MORGAN, BAILEY MICHELLE is the busiest examiner, with 2 pending matters. That allocation makes this examiner the clearest point for coordinated review, although the remaining matters still require separate tracking across the other assignments.
The difference between examiner and art-unit counts indicates that examiner distribution is broader than art-unit distribution. Counsel may benefit from maintaining art-unit-level claim strategy while preserving examiner-specific response records and interview planning.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (11%) |
| Double-patenting + other | 4 (44%) |
| Multi-statute (no §101) | 4 (44%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MORGAN, BAILEY MICHELLE | 2 | 56.3% | +58.3% |
| KIM, SEONG JONG | 1 | 25.0% | +0.0% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
| RAHMAN, MASUDUR | 1 | 72.9% | +31.7% |
| HEITMEIER, KENDALL NICOLE | 1 | 65.1% | +41.1% |
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.7% |
| HUTTER, GILLIAN A | 1 | 54.5% | +46.0% |
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002928 | NOVEL HETEROARYL-SUBSTITUTED PYRAZINE DERIVATIVES AS PESTICIDES | HEITMEIER, KENDALL NICOLE | 3d overdue |
| 18366306 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES | RAHMAN, MASUDUR | 34d |
| 17995750 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | RODRIGUEZ-GARCIA, VALERIE | 34d |
| 18730668 | MOLIDUSTAT FORMULATIONS AND METHODS OF USE FOR TREATMENT OF ANEMIA IN CATS | KIM, SEONG JONG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002928 | NOVEL HETEROARYL-SUBSTITUTED PYRAZINE DERIVATIVES AS PESTICIDES | HEITMEIER, KENDALL NICOLE | 3d overdue |
| 18366306 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES | RAHMAN, MASUDUR | 34d |
| 17995750 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | RODRIGUEZ-GARCIA, VALERIE | 34d |
| 18262949 | VACCINE COMPOSITION FOR BREAKING SELF-TOLERANCE | MORGAN, BAILEY MICHELLE | — |
| 18262975 | VACCINE COMPOSITION FOR BREAKING SELF-TOLERANCE | MORGAN, BAILEY MICHELLE | — |
| 17795652 | PHARMACEUTICAL COMPOSITION FOR CONTROLLING PARASITES ON NON-HUMAN ORGANISMS | HUTTER, GILLIAN A | — |
| 17767018 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | NESTOR, DONNA MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1621 | 3 |
| 1645 | 2 |
| 1623 | 1 |
| 1633 | 1 |
| 1625 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18730668 | MOLIDUSTAT FORMULATIONS AND METHODS OF USE FOR TREATMENT OF ANEMIA IN CATS | KIM, SEONG JONG | 1621 | §102§103§112 | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18690087 | NEW QUINOLINE DERIVATIVES | SHTERENGARTS, SAMANTHA L | 1623 | §102DP | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18366306 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES | RAHMAN, MASUDUR | 1633 | §103§112 | Non-Final OA | 34d | Pending | Aug 07, 2023 |
| 18262949 | VACCINE COMPOSITION FOR BREAKING SELF-TOLERANCE | MORGAN, BAILEY MICHELLE | 1645 | §103§112DP | Non-Final OA | — | Pending | Jul 26, 2023 |
| 18262975 | VACCINE COMPOSITION FOR BREAKING SELF-TOLERANCE | MORGAN, BAILEY MICHELLE | 1645 | §103§112DP | Non-Final OA | — | Pending | Jul 26, 2023 |
| 18002928 | NOVEL HETEROARYL-SUBSTITUTED PYRAZINE DERIVATIVES AS PESTICIDES | HEITMEIER, KENDALL NICOLE | 1621 | §102§103§112Other | Final Rejection | 3d overdue | Pending | Dec 22, 2022 |
| 17995750 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | RODRIGUEZ-GARCIA, VALERIE | 1621 | §103§112 | Non-Final OA | 34d | Pending | Oct 07, 2022 |
| 17795652 | PHARMACEUTICAL COMPOSITION FOR CONTROLLING PARASITES ON NON-HUMAN ORGANISMS | HUTTER, GILLIAN A | 1625 | §103 | Non-Final OA | — | Pending | Jul 27, 2022 |
| 17767018 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | NESTOR, DONNA MICHELLE | 1627 | §103§112DP | Non-Final OA | — | Pending | Apr 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialElanco Animal Health GmbH has 9 pending office actions as of October 2026, spread across 6 art units and 8 examiners.
Bailey Michelle Morgan has the most, with 2 of Elanco Animal Health GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
